{"id":"ezetimibe-simvastatin-10-40","safety":{"commonSideEffects":[{"rate":"2-3%","effect":"Myalgia"},{"rate":"1-3%","effect":"Elevated liver transaminases"},{"rate":"5-7%","effect":"Headache"},{"rate":"2-4%","effect":"Abdominal pain"},{"rate":"2-3%","effect":"Diarrhea"},{"rate":"<0.1%","effect":"Rhabdomyolysis"}]},"_chembl":{"chemblId":"CHEMBL1201391","moleculeType":"Small molecule","molecularWeight":"436.59"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Ezetimibe selectively inhibits the Niemann-Pick C1-like 1 (NPC1L1) transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption. Simvastatin is an HMG-CoA reductase inhibitor that decreases cholesterol synthesis in the liver. Together, this combination provides complementary mechanisms to lower LDL cholesterol and triglycerides while raising HDL cholesterol.","oneSentence":"Ezetimibe/simvastatin reduces blood cholesterol by blocking intestinal cholesterol absorption (ezetimibe) and inhibiting hepatic cholesterol synthesis (simvastatin).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:36.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and mixed dyslipidemia"},{"name":"Cardiovascular risk reduction in patients requiring LDL-C lowering"}]},"trialDetails":[{"nctId":"NCT00166530","phase":"PHASE4","title":"EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-11","conditions":"Atherosclerosis","enrollment":367},{"nctId":"NCT00202878","phase":"PHASE3","title":"IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-10-17","conditions":"Hypercholesterolemia, Myocardial Infarction","enrollment":18144},{"nctId":"NCT00442897","phase":"PHASE4","title":"Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Hypercholesterolemia","enrollment":229},{"nctId":"NCT00423579","phase":"PHASE4","title":"The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-07-01","conditions":"Hypercholesterolemia, Coronary Disease","enrollment":120},{"nctId":"NCT00535405","phase":"PHASE3","title":"A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-11","conditions":"Hypercholesterolemia","enrollment":1289},{"nctId":"NCT00409773","phase":"PHASE3","title":"Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-01","conditions":"Hypercholesterolemia, Metabolic Syndrome","enrollment":1143},{"nctId":"NCT00782184","phase":"PHASE3","title":"Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-11","conditions":"Hypercholesterolemia","enrollment":250},{"nctId":"NCT00462748","phase":"PHASE3","title":"A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-03","conditions":"Hypercholesterolemia","enrollment":786},{"nctId":"NCT00092677","phase":"PHASE3","title":"An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-01","conditions":"Aortic Stenosis","enrollment":1873},{"nctId":"NCT00271817","phase":"PHASE3","title":"To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":1220},{"nctId":"NCT00862251","phase":"PHASE3","title":"Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2009-04","conditions":"Cardiovascular Disorder, Diabetes Mellitus","enrollment":808},{"nctId":"NCT03884452","phase":"PHASE3","title":"Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-05-03","conditions":"Familial Hypercholesterolemia","enrollment":50},{"nctId":"NCT01420328","phase":"NA","title":"To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2011-05-01","conditions":"Inflammation","enrollment":20},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT03885921","phase":"PHASE3","title":"Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-10-25","conditions":"Hypercholesterolemia","enrollment":44},{"nctId":"NCT00413972","phase":"PHASE3","title":"Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-04","conditions":"Hypercholesterolemia","enrollment":392},{"nctId":"NCT01070966","phase":"","title":"Vytorin Reexamination Study (0653A-174)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07","conditions":"Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH)","enrollment":2089},{"nctId":"NCT00423488","phase":"PHASE3","title":"Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07-12","conditions":"Hypercholesterolemia, Diabetes Mellitus, Type 2, Coronary Disease","enrollment":93},{"nctId":"NCT01077830","phase":"","title":"An Observational Follow-Up Study of the Incidence of Cancer and Mortality in Patients From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Trial (MK-0653A-043-10)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-03","conditions":"Cancer","enrollment":1392},{"nctId":"NCT00652327","phase":"PHASE4","title":"Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":83},{"nctId":"NCT00129402","phase":"PHASE3","title":"Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-08","conditions":"Hypercholesterolemia","enrollment":248},{"nctId":"NCT00879710","phase":"NA","title":"Effect of Diabetes Mellitus on Cholesterol Metabolism","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2008-08","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia","enrollment":57},{"nctId":"NCT00687076","phase":"PHASE4","title":"Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2004-04","conditions":"Peripheral Arterial Disease","enrollment":102},{"nctId":"NCT01420549","phase":"PHASE3","title":"Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2013-03","conditions":"Hypercholesterolemia, Dyslipidemia","enrollment":129},{"nctId":"NCT00819403","phase":"PHASE4","title":"Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2009-01","conditions":"Metabolic Syndrome","enrollment":15},{"nctId":"NCT03543774","phase":"PHASE4","title":"Lipid-lowering Therapies in Vietnamese Chronic Kidney Disease Population","status":"UNKNOWN","sponsor":"Hue University of Medicine and Pharmacy","startDate":"2018-06-15","conditions":"Hypercholesterolemia, Chronic Kidney Diseases","enrollment":30},{"nctId":"NCT02304926","phase":"NA","title":"Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia","status":"COMPLETED","sponsor":"Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana","startDate":"2009-01","conditions":"Dyslipidemia","enrollment":42},{"nctId":"NCT00120289","phase":"PHASE3","title":"Niacin Plus Statin to Prevent Vascular Events","status":"TERMINATED","sponsor":"Axio Research. LLC","startDate":"2005-09","conditions":"Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident","enrollment":3414},{"nctId":"NCT00738296","phase":"PHASE4","title":"Vytorin on Carotid Intima-media Thickness and Overall Rigidity","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2005-04","conditions":"Cardiovascular Diseases","enrollment":90},{"nctId":"NCT01520077","phase":"PHASE1","title":"Vytorin in the Treatment of Alopecia Areata","status":"COMPLETED","sponsor":"University of Miami","startDate":"2011-07","conditions":"Alopecia Areata","enrollment":29},{"nctId":"NCT00461630","phase":"PHASE3","title":"Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-01","conditions":"Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus","enrollment":25673},{"nctId":"NCT00738972","phase":"PHASE3","title":"Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)","status":"TERMINATED","sponsor":"Fundación Lindavista del Corazón AC","startDate":"2008-01","conditions":"Hypertension","enrollment":12},{"nctId":"NCT00932620","phase":"PHASE4","title":"Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL)","status":"COMPLETED","sponsor":"University of Ioannina","startDate":"2009-06","conditions":"Hypercholesterolemia","enrollment":100},{"nctId":"NCT00664469","phase":"PHASE3","title":"INdians Followed for INtensive Lipid Lowering Treatment and Its safetY","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2007-08","conditions":"Hypercholesterolemia","enrollment":64},{"nctId":"NCT00905905","phase":"PHASE4","title":"Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction","status":"COMPLETED","sponsor":"Brasilia Heart Study Group","startDate":"2009-05","conditions":"Myocardial Infarction","enrollment":40},{"nctId":"NCT00861731","phase":"PHASE4","title":"Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy","status":"UNKNOWN","sponsor":"Azienda Ospedaliero Universitaria di Sassari","startDate":"2008-11","conditions":"Hypercholesterolemia, Chronic Nephropathy","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vytorin"],"phase":"phase_3","status":"active","brandName":"ezetimibe/simvastatin 10/40","genericName":"ezetimibe/simvastatin 10/40","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ezetimibe/simvastatin reduces blood cholesterol by blocking intestinal cholesterol absorption (ezetimibe) and inhibiting hepatic cholesterol synthesis (simvastatin). Used for Hypercholesterolemia and mixed dyslipidemia, Cardiovascular risk reduction in patients requiring LDL-C lowering.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}